GREENLIGHT BIOSCIENCES HOLDI (GRNA)       1.11  -0.01 (-0.89%)

1.11  -0.01 (-0.89%)

US39536G1058 - Common Stock - After market: 1.14 +0.03 (+2.7%)

GREENLIGHT BIOSCIENCES HOLDI1.11

NASDAQ:GRNA (2/3/2023, 7:00:01 PM)-0.01 (-0.89%)

After market: 1.14 +0.03 (+2.7%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Biotechnology

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-09 2022-11-09/amc Earnings (Next) N/A N/A
Ins Owners 20.57% Inst Owners N/A
Market Cap 168.22M Shares 151.55M
PE N/A Fwd PE N/A
Dividend Yield N/A Analysts 85
IPO 01-14 2021-01-14

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GRNA Daily chart

Company Profile

GreenLight Biosciences Holdings PBC operates as a biotechnology company, which makes ribonucleic acid (RNA) products for human therapies and agriculture. The company is headquartered in Medford, Massachusetts. The company went IPO on 2021-01-14. The firm is focused on Ribonucleic acid (RNA) research, design, and manufacturing for human, animal, and plant health. The firm has developed technology to create high-performing, natural ribonucleic acid (RNA) products to address global sustainability challenges and promote healthier plants, foods, and people. The firm is engaged in the cell-free biomanufacturing platform. This platform enables the making of complex biological molecules nucleic acids, peptides, carbohydrates, and many others which allows manufacturing products at a lower cost than traditional methods using fermentation. The platform is used to develop and commercialize products. The firm's pipeline for plant and animal health includes Colorado potato beetle, Botrytis cinerea, Varroa mites, Fungicides, Grapevine powdery mildew, Fusarium Head Blight (FHB), Lepidoptera, and Powdery mildew.

Company Info

GREENLIGHT BIOSCIENCES HOLDI

200 Boston Avenue, Suite 3100

Medford MASSACHUSETTS

P: 16176168188.0

Employees: 312

Website: https://greenlightbiosciences.com/

GRNA News

News Image4 days ago - GreenLight BiosciencesGreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidateNews Image4 days ago - GreenLight BiosciencesGreenLight Biosciences receives approval to initiate Phase I/II clinical trial of Covid-19 mRNA vaccine candidate

The Rwanda FDA has given regulatory approval to GreenLight to start a Phase I/II clinical trial of its Covid-19 vaccine candidate in Rwanda. This phase...

News Imagea month ago - GreenLight BiosciencesGreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer VaccinesNews Imagea month ago - GreenLight BiosciencesGreenLight Biosciences and Epivax Therapeutics Sign Exclusive Collaboration Agreement to Develop Personalized Cancer Vaccines

The effort will combine GreenLight’s mRNA design and manufacturing expertise with EpiVax’s advanced Ancer® pipeline for personalized cancer vaccine...

News Image2 months ago - The Motley FoolWhy Greenlight Biosciences Stock Was in the Red Today

The company reportedly turned down offers to go private.

News Image3 months ago - GreenLight BiosciencesGreenLight Biosciences Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

GRNA Twits

Here you can normally see the latest stock twits on GRNA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example